• Thurs news: Sage R&D layoffs. Another Sanofi radiopharma deal. Novartis loses bid to block generic. Kezar lupus trial stopped. Why are so many pharmacies closing. See more on our front page

The Biotech Bubble is...





It is somewhere in-between A and B. Good biotech drugs aimed at large indications that are Phase II/III or entering the market for large indications will do OK. Niche drugs and those that are preclinical will have a hard time staying funded.